Competitor Landscape: Psoriasis
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted Sociable Pharma’s view of the disease landscape
Landscape Updates: ‘Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher; Timeline forecasts for each approved product’s lifecycle management initiatives; ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies
Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
Approved Product Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
Scope
The briefing is based on Sociable Pharma’s analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)
Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher – these are outlined in the report Appendix
Forecasts are presented in pipeline forecast figures & detailed tables
‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies is also provided
Key Highlights
Certolizumab pegol may find a niche in PsO patients looking to conceive, due to its global approval for use in women of childbearing age
Novartis seeks to identify additional points of differentiation for secukinumab vs. competing biologics by further exploring efficacy and safety in pediatrics and alternative dosing formulations & strategies
BMS-986165 could become the first TYK-2 inhibitor to be approved for PsO, pending positive data from the recently registered Phase III trials
Reasons to Buy
Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
Reviews ongoing lifecycle management strategies for existing players in the market
A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts
AbGenomics
Affibody AB
Akros Pharma
Almirall
AmDerma Pharmaceuticals
Amgen
AnaptysBio
Arcutis
Assistance Publique - Hôpitaux de Paris
AstraZeneca
Atridia Pty
Avillion Merck
Baliopharm
Bausch Health
Bayer
Betta Pharmaceuticals
Biocad
BioMimetix
Biotech Pharmaceutical
BMS
Boehringer Ingelheim
Can-Fite BioPharma
Celgene
Crescendo Biologics
Crescita Therapeutics
DNX Biopharmaceuticals
Dr. Reddy's
Durect Corporation
Escalier Biosciences
Evelo Biosciences
Exicure
Galderma R&D
Galectin
GSK
ILTOO Pharma
Immune Pharma
Innovation Pharma
Inventiva
Janssen
Japan Tobacco
Johnson & Johnson
Kadmon Corporation
Kaken Pharmaceuticals Co.
Kangstem Biotech
Kymab
LEO Pharma
Lilly
Lycera
Maruho North America Inc.
MC2 Therapeutics
Menlo Therapeutics
MetrioPharm AG
MiCal 1
Novan
Novartis
Noxopharm
Nuevolution
Ortho Dermatologics
Pfizer
Polichem S.A.
Promius Pharma
Prothena Corporation
Realm Therapeutics
Reata Pharmaceuticals
Rigel
Saniona
Sareum
Sienna Biopharmaceuticals
Sun Pharma
Syntrix
Takeda
Theramab
Tianjin Hemay Bio-Tech
UCB
Valeant Pharmaceuticals
Vitae Pharmaceuticals
XenoPort
Zai Lab
Ziarco Pharma
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.